<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is postulated that inhibition of cytosolic phospholipase A(2) alpha (cPLA(2)α) can reduce severity of <z:hpo ids='HP_0001297'>stroke</z:hpo> injury </plain></SENT>
<SENT sid="1" pm="."><plain>This is supported by the finding that cPLA(2)α-deficient mice are partially protected from transient, focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The object of this study was to determine the effect of cPLA(2)α inhibition with <z:chebi fb="0" ids="2341">arachidonyl trifluoromethyl ketone</z:chebi> (ATK) on <z:hpo ids='HP_0001297'>stroke</z:hpo> injury in mice </plain></SENT>
<SENT sid="3" pm="."><plain>Male C57BL/6 mice were subjected to 1h of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> followed by 24 or 72 h of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Mice were treated with ATK or vehicle by intermittent intraperitoneal injection or continuous infusion via an implanted infusion pump </plain></SENT>
<SENT sid="5" pm="."><plain>ATK injections 1h before and then 1 and 6h after the start of reperfusion significantly reduced infarction volumes in striatum and hemisphere after 24h of reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>ATK did not reduce injury if it was not administered before <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or was not administered after 6h of reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>Intermittent doses of ATK failed to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume after 72 h of reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>Continuous infusion with ATK throughout 72h of reperfusion significantly reduced cortical and whole hemispheric <z:mpath ids='MPATH_124'>infarct</z:mpath> volume compared to vehicle treatment </plain></SENT>
<SENT sid="9" pm="."><plain>Following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion, ATK treatment significantly reduced brain <z:chebi fb="79" ids="53407">PLA</z:chebi>(2) activity </plain></SENT>
<SENT sid="10" pm="."><plain>These results are the first to demonstrate a therapeutic effect of cPLA(2)α inhibition on <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and reperfusion injury and define a therapeutic time window </plain></SENT>
<SENT sid="11" pm="."><plain>cPLA(2)α activity augments injury in the <z:hpo ids='HP_0011009'>acute</z:hpo> and delayed phases of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and reperfusion injury </plain></SENT>
<SENT sid="12" pm="."><plain>We conclude that cPLA(2)α inhibition may be clinically useful if started before initiation of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>